A test called a Decipher Genomic Classifier is shedding light on the heterogeneity of prostate cancer, offering a clearer picture by analyzing the unique biology of an individual's cancer.
Hi. ArteraAI Prostate has strong Phase III randomized control data (Level I-B type validation for both prognostic and predictive use in prostate cancer.
While Decipher AI Prostate has strong Phase III randomized data (Level I-B type validation) for prognostic use in prostate cancer, it lacks the same Level I-B type validation) for predictive use in prostate cancer. Decipher has clinical data suggesting predictive value, but not nearly as strong clinical data for predictive value as ArteraAI.
The decipher test along with certain other genetic tests are invaluable tools to help manage treatment choices for prostate cancer.
My post salvage prostatectomy Decipher score was 0.95 Gleason 9 (4+5) Stage T3N1. Post surgery PSA nadir was 0.40.
I originally was diagnosed with low risk Gleason 6 prostate cancer in 2020. I asked my RO/MO for genetic testing on the biopsy sample and he told me that he didn’t see the point. I opted for focal LDR brachytherapy with the belief that I’d put cancer behind me once and for all. That was wishful thinking. Had a decipher test been performed and shown a high score. I would’ve opted for RALP the first time before the cancer spread outside the prostate.
After salvage RALP, I had 31 sessions of I MRT, which included treatment to the lymph node basin and a boost to the left obturnator lymph node that couldn’t be reached safely during surgery.
I did 11 months of ADT, which included ORGOVYX and abiraterone. The goal was 18 months, but we had to stop early due to unmanageable side effects.
Hi Bob. I'm sorry you had that terrible experience, and I can relate to the unmanageable side effects of ADT. Prostate cancer thought leaders need to do more to promote genomic testing for all men with prostate cancer. Genomic testing is significantly underutilized in the community-based (non-academic) setting. Knowledge is power. Thanks for your comment.
Hi
Is ARTERA AI also used for future predictions and prognosis giving effective info such as DECIPHER does?
Hi. ArteraAI Prostate has strong Phase III randomized control data (Level I-B type validation for both prognostic and predictive use in prostate cancer.
While Decipher AI Prostate has strong Phase III randomized data (Level I-B type validation) for prognostic use in prostate cancer, it lacks the same Level I-B type validation) for predictive use in prostate cancer. Decipher has clinical data suggesting predictive value, but not nearly as strong clinical data for predictive value as ArteraAI.
I wrote a Substack Article about ArteraAI Prostaste here: https://www.prostatecancersecrets.com/p/artificial-intelligence-and-prostate
The decipher test along with certain other genetic tests are invaluable tools to help manage treatment choices for prostate cancer.
My post salvage prostatectomy Decipher score was 0.95 Gleason 9 (4+5) Stage T3N1. Post surgery PSA nadir was 0.40.
I originally was diagnosed with low risk Gleason 6 prostate cancer in 2020. I asked my RO/MO for genetic testing on the biopsy sample and he told me that he didn’t see the point. I opted for focal LDR brachytherapy with the belief that I’d put cancer behind me once and for all. That was wishful thinking. Had a decipher test been performed and shown a high score. I would’ve opted for RALP the first time before the cancer spread outside the prostate.
After salvage RALP, I had 31 sessions of I MRT, which included treatment to the lymph node basin and a boost to the left obturnator lymph node that couldn’t be reached safely during surgery.
I did 11 months of ADT, which included ORGOVYX and abiraterone. The goal was 18 months, but we had to stop early due to unmanageable side effects.
Hi Bob. I'm sorry you had that terrible experience, and I can relate to the unmanageable side effects of ADT. Prostate cancer thought leaders need to do more to promote genomic testing for all men with prostate cancer. Genomic testing is significantly underutilized in the community-based (non-academic) setting. Knowledge is power. Thanks for your comment.